Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Mem. Inst. Oswaldo Cruz ; 106(8): 986-992, Dec. 2011. graf
Article in English | LILACS | ID: lil-610974

ABSTRACT

In this study, we evaluated whether human serum and lipoproteins, especially high-density lipoprotein (HDL), affected serum amyloid A (SAA)-induced cytokine release. We verified the effects of SAA on THP-1 cells in serum-free medium compared to medium containing human serum or lipoprotein-deficient serum. SAA-induced tumour necrosis factor-alpha (TNF-α) production was higher in the medium containing lipoprotein-deficient serum than in the medium containing normal human serum. The addition of HDL inhibited the SAA-induced TNF-α release in a dose-dependent manner. This inhibitory effect was specific for HDL and was not affected by low-density lipoprotein or very low-density lipoprotein. In human peripheral blood mononuclear cells, the inhibitory effect of HDL on TNF-α production induced by SAA was less pronounced. However, this effect was significant when HDL was added to lipoprotein-deficient medium. In addition, a similar inhibitory effect was observed for interleukin-1 beta release. These findings confirm the important role of HDL and support our previous hypothesis that HDL inhibits the effects of SAA during SAA transport in the bloodstream. Moreover, the HDL-induced reduction in the proinflammatory activity of SAA emphasizes the involvement of SAA in diseases, such as atherosclerosis, that are characterized by low levels of HDL.


Subject(s)
Humans , Interleukin-1beta/biosynthesis , Leukocytes, Mononuclear/metabolism , Lipoproteins, HDL/pharmacology , Serum Amyloid A Protein/antagonists & inhibitors , Tumor Necrosis Factor-alpha/biosynthesis , Culture Media, Serum-Free , Interleukin-1beta/drug effects , Leukocytes, Mononuclear/drug effects , Lipoproteins, LDL/pharmacology , Lipoproteins, VLDL/pharmacology , Monocytes/drug effects , Monocytes/metabolism , Serum Amyloid A Protein/pharmacology
2.
Experimental & Molecular Medicine ; : 325-333, 2009.
Article in English | WPRIM | ID: wpr-136589

ABSTRACT

Serum amyloid A (SAA) has been regarded as an important mediator of inflammatory responses. The effect of several formyl peptide receptor-like 1 (FPRL1) ligands on the production of IL-8 by SAA was investigated in human neutrophils. Among the ligands tested, LL-37 was found to specifically inhibit SAA-induced IL-8 production in transcriptional and post-transcriptional levels. Since SAA stimulated IL-8 production via ERK and p38 MAPK in human neutrophils, we tested the effect of LL-37 on SAA induction for these two MAPKs. LL-37 caused a dramatic inhibition of ERK and p38 MAPK activity, which is induced by SAA. LL-37 was also found to inhibit SAA-stimulated neutrophil chemotactic migration. Further, the LL-37-induced inhibitory effect was mediated by FPRL1. Our findings indicate that LL-37 is expected to be useful in the inhibition of SAA signaling and for the development of drugs against SAA-related inflammatory diseases.


Subject(s)
Animals , Humans , Rats , Antimicrobial Cationic Peptides/pharmacology , Cell Line, Tumor , Cell Movement , Chemotaxis, Leukocyte , Interleukin-8/biosynthesis , MAP Kinase Kinase Kinases/metabolism , Neutrophils/drug effects , Proto-Oncogene Proteins/metabolism , Receptors, Formyl Peptide/metabolism , Receptors, Lipoxin/metabolism , Serum Amyloid A Protein/antagonists & inhibitors , Signal Transduction , Transcription, Genetic
3.
Experimental & Molecular Medicine ; : 325-333, 2009.
Article in English | WPRIM | ID: wpr-136588

ABSTRACT

Serum amyloid A (SAA) has been regarded as an important mediator of inflammatory responses. The effect of several formyl peptide receptor-like 1 (FPRL1) ligands on the production of IL-8 by SAA was investigated in human neutrophils. Among the ligands tested, LL-37 was found to specifically inhibit SAA-induced IL-8 production in transcriptional and post-transcriptional levels. Since SAA stimulated IL-8 production via ERK and p38 MAPK in human neutrophils, we tested the effect of LL-37 on SAA induction for these two MAPKs. LL-37 caused a dramatic inhibition of ERK and p38 MAPK activity, which is induced by SAA. LL-37 was also found to inhibit SAA-stimulated neutrophil chemotactic migration. Further, the LL-37-induced inhibitory effect was mediated by FPRL1. Our findings indicate that LL-37 is expected to be useful in the inhibition of SAA signaling and for the development of drugs against SAA-related inflammatory diseases.


Subject(s)
Animals , Humans , Rats , Antimicrobial Cationic Peptides/pharmacology , Cell Line, Tumor , Cell Movement , Chemotaxis, Leukocyte , Interleukin-8/biosynthesis , MAP Kinase Kinase Kinases/metabolism , Neutrophils/drug effects , Proto-Oncogene Proteins/metabolism , Receptors, Formyl Peptide/metabolism , Receptors, Lipoxin/metabolism , Serum Amyloid A Protein/antagonists & inhibitors , Signal Transduction , Transcription, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL